The relationship between metabolic status and levels of adiponectin and ghrelin in lean women with polycystic ovary syndrome

References

• Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81: 19–25
   Web of Science ®Google Scholar
• Knochenhauser E S, Key T J, Kahasar-Miller M, Waggoner W, Boots L R, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 1998; 83: 3078–3082
   PubMed Web of Science ®Google Scholar
• Hopkinson Z E, Sattar N, Fleming R, Greer I A. Polycystic ovarian syndrome: the metabolic syndrome comes to gynecology. Br Med J 1998; 317: 329–332
   PubMed Web of Science ®Google Scholar
• Wild S, Pierpoint T, McKeigue P, Jacobs H. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin Endocrinol (Oxf) 2000; 52: 595–600
   PubMed Web of Science ®Google Scholar
• Christian R C, Dumesic D A, Behrenbeck T, Oberg A L, Sheedy P F, 2nd, Fitzpatrick L A. Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88: 2562–2568
   PubMed Web of Science ®Google Scholar
• Carmina E, Napoli N, Longo R A, Rini G B, Lobo R A. Metabolic syndrome in polycystic ovary syndrome (PCOS): lower prevalence in southern Italy than in the USA and the influence of criteria for the diagnosis of PCOS. Eur J Endocrinol 2006; 154: 141–145
   PubMed Web of Science ®Google Scholar
• Carmina E, Lobo R A. Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women. J Clin Endocrinol Metab 1999; 84: 1897–1899
   PubMed Web of Science ®Google Scholar
• Dunaif A, Segal K R, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989; 38: 1165–1174
   PubMed Web of Science ®Google Scholar
• Ovalle F, Azziz R. Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus. Fertil Steril 2002; 77: 1095–1105
   PubMed Web of Science ®Google Scholar
• Acien P, Quereda F, Matallin P, Villarroya E, Lopez-Fernandez J A, Acien M, Mauri M, Alfayate R. Insulin, androgens, and obesity in women with and without polycystic ovary syndrome: a heterogeneous group of disorders. Fertil Steril 1999; 72: 32–40
   PubMed Web of Science ®Google Scholar
• Apridonidze T, Essah P A, Iuorno M J, Nestler J E. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90: 1929–1935
   PubMed Web of Science ®Google Scholar
• Meier U, Gressner A M. Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin, and resistin. Clin Chem 2004; 50: 1511–1525
   PubMed Web of Science ®Google Scholar
• Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001; 7: 941–946
   PubMed Web of Science ®Google Scholar
• Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002; 8: 1288–1295
   PubMed Web of Science ®Google Scholar
• Goldstein B J, Scalia R. Adiponectin: a novel adipokine linking adipocytes and vascular function. J Clin Endocrinol Metab 2004; 89: 2563–2568
   PubMed Web of Science ®Google Scholar
• Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 2004; 109(Suppl I)III27–III32
   PubMed Web of Science ®Google Scholar
• Kravariti M, Naka K K, Kalantaridou S N, Kazakos N, Katsouras C S, Makrigiannakis A, Paraskevaidis E A, Chrousos G P, Tsatsoulis A, Michalis L K. Predictors of endothelial dysfunction in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90: 5088–5095
   PubMed Web of Science ®Google Scholar
• Orio F, Jr, Palomba S, Cascella T, Milan G, Mioni R, Pagano C, Zullo F, Colao A, Lombardi G, Vettor R. Adiponectin levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88: 2619–2623
   PubMed Web of Science ®Google Scholar
• Orio F, Jr, Palomba S, Cascella T, De Simone B, Manguso F, Savastano S, Russo T, Tolino A, Zullo F, Lombardi G, et al. Improvement of endothelial structure and function after metformin treatment in young normal-weight women with polycystic ovary syndrome: results of 6-month study. J Clin Endocrinol Metab 2005; 90: 6072–6076
   PubMed Web of Science ®Google Scholar
• Sorensen M B, Franks S, Robertson C, Pennel D J, Collins P. Severe endothelial dysfunction in young women with polycystic ovary syndrome is only partially explained by known cardiovascular risk factors. Clin Endocrinol (Oxf) 2006; 65: 655–659
   PubMed Web of Science ®Google Scholar
• Carmassi F, De Negri F, Fioriti R, De Giorgi A, Ginnarelli C, Fruzzetti F, Pedrinelli R, Dell'Omo G, Bersi C. Insulin resistance causes impaired vasodilatation and hypofibrinolysis in young women with polycystic ovary syndrome. Thromb Res 2005; 116: 207–214
   PubMed Web of Science ®Google Scholar
• Tarkur I, Arslan B C, Canturk Z, Turmen E, Sahin T, Duman C. Endothelial dysfunction in young women with polycystic ovary syndrome relationship with insulin resistance and low-grade chronic inflammation. J Clin Endocrinol Metab 2004; 89: 5592–5596
   PubMed Web of Science ®Google Scholar
• Broglio F, Arvat E, Benso A, Gottero C, Muccioli G, Papotti M, van der Lely A J, Deghenghi R, Ghigo E. Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans. J Clin Endocrinol Metab 2001; 86: 5083–5086
   PubMed Web of Science ®Google Scholar
• Nakazato M, Murakami N, Date Y, Kojima M, Matsuo H, Kangawa K, Matsukura S. A role for ghrelin in the central regulation of feeding. Nature 2001; 409: 194–198
   PubMed Web of Science ®Google Scholar
• Wren A M, Small C J, Ward H L, Murphy K G, Dakin C L, Taheri S, Kennedy A R, Roberts G H, Morgan D G, Ghatei M A, et al. The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion. Endocrinology 2000; 141: 4325–4328
   PubMed Web of Science ®Google Scholar
• Ghigo E, Broglio F, Arvat E, Maccario M, Papotti M, Muccioli G. Ghrelin: more than a natural GH secretagogue and/or an orexigenic factor. Clin Endocrinol (Oxf) 2005; 62: 1–17
   PubMed Web of Science ®Google Scholar
• Hosoda H, Kojima M, Kangawa K. Biological, physiological, and pharmacological aspects of ghrelin. J Pharmacol Sci. 2006; 100: 398–410
   PubMed Web of Science ®Google Scholar
• Hatch R, Rosenfield R L, Kim M H, Tredway D. Hirsutism: implications, etiology, and management. Am J Obstet Gynecol 1981; 140: 815–830
   PubMed Web of Science ®Google Scholar
• Matthews D R, Hosker J P, Rudenski A S, Naylor B A, Treacher D F, Turner R C. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412–419
   PubMed Web of Science ®Google Scholar
• Dwenger A. Radioimmunoassays: an overview. J Clin Chem Clin Biochem 1984; 22: 883–894
   PubMedGoogle Scholar
• Patterson M, Murphy K G, Le Roux C W, Ghatei M A, Bloom S. Characterization of ghrelin-like immunoreactivity in human plasma. J Clin Endocrinol Metab 2005; 90: 2205–2211
   PubMed Web of Science ®Google Scholar
• Cnop M, Havel P J, Utzschneider K M, Carr D B, Sinha M K, Boyko E J, Retzlaff B M, Knopp R H, Brunzell J D, Kahn S E. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 2003; 46: 459–469
   PubMed Web of Science ®Google Scholar
• Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K, et al. Plasma concentrations of novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000; 20: 1595–1599
   PubMed Web of Science ®Google Scholar
• Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley R E, Tataranni P A. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86: 1930–1935
   PubMed Web of Science ®Google Scholar
• Milewicz A, Zatonska K, Demissie M, Jedrzejczuk D, Dunajska K, Ilow R, Lwow F. Serum adiponectin concentration and cardiovascular risk factors in climacteric women. Gynecol Endocrinol 2005; 20: 68–73
   PubMed Web of Science ®Google Scholar
• Berg A H, Combs T P, Scherer P E. ACRP 30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab 2002; 13: 84–89
   PubMed Web of Science ®Google Scholar
• Kubota N, Tarauchi Y, Yamauchi T, Kubota T, Moroi M, Matsui J, Eto K, Yamashita T, Kamon J, Satoh H, et al. Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 2002; 277: 25863–25866
   PubMed Web of Science ®Google Scholar
• Spranger J, Mohlig M, Wegewitz, RistowM, Pfeiffer A, Schill T, Schlosser H, Brabant G, Schofl C. Adiponectin is independently associated with insulin sensitivity in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2004; 61: 738–746
   PubMed Web of Science ®Google Scholar
• Ravussin E, Smith S R. Increased fat intake, impaired fat oxidation, and failure of fat cell proliferation result in ectopic fat storage, insulin resistance, and type 2 diabetes mellitus. Ann NY Acad Sci 2002; 967: 363–378
   PubMed Web of Science ®Google Scholar
• Lamarche B. Abdominal obesity and its metabolic complications: implications for the risk of ischaemic heart disease. Coron Artery Dis 1998; 9: 473–481
   PubMed Web of Science ®Google Scholar
• Bosello O, Zamboni M. Visceral obesity and metabolic syndrome. Obes Rev 2000; 1: 47–56
   PubMedGoogle Scholar
• Ardawi M S, Rouzi A A. Plasma adiponectin and insulin resistance in women with polycystic ovary syndrome. Fertil Steril 2005; 83: 1708–1716
   PubMed Web of Science ®Google Scholar
• Ducluzeau P H, Cousin P, Malvoisin E, Bornet H, Vidal H, Laville M, Pugeat M. Glucose-to-insulin ratio rather than sex hormone-binding globulin and adiponectin levels is the best predictor of insulin resistance in nonobese women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88: 3626–3631
   PubMed Web of Science ®Google Scholar
• Panidis D, Kourtis A, Farmakiotis D, Mouslech T, Rousso D, Koliakos G. Serum adiponectin levels in women with polycystic ovary syndrome. Hum Reprod 2003; 18: 1790–1796
   PubMed Web of Science ®Google Scholar
• Nishizawa H, Shimomura I, Kishida K, Maeda N, Kuriyama H, Nagaretani H, Matsuda M, Kondo H, Furuyama N, Kihara S, et al. Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes 2002; 51: 2734–2741
   PubMed Web of Science ®Google Scholar
• Heinonen S, Korhonen S, Helisalmi S, Koivunen R, Tapanainen J, Hippelainen M, Laakso M. Associations between two single nucleotide polymorphisms in the adiponectin gene and polycystic ovary syndrome. Gynecol Endocrinol 2005; 21: 165–169
   PubMed Web of Science ®Google Scholar
• Xita N, Georgiou I, Chatzikyriakidou A, Vounatsou M, Papassotiriou G P, Papassotiriou I, Tsatsoulis A. Effect of adiponectin gene polymorphisms on circulating adiponectin and insulin resistance indexes in women with polycystic ovary syndrome. Clin Chem 2005; 51: 416–423
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Hirose H, Saito I, Tomita M, Taniyama M, Matsubara K, Okazaki Y, Ishii T, Nishikai K, Saruta T. Correlation of the adipocyte-derived protein adiponectin with insulin resistance index and serum high-density lipoprotein-cholesterol, independent of body mass index, in the Japanese population. Clin Sci (Lond) 2002; 103: 137–142
   PubMed Web of Science ®Google Scholar
• Pellme F, Smith U, Funahashi T, Matsuzawa Y, Brekke H, Wiklund O, Taskinen M R, Jansson P A. Circulating adiponectin levels are reduced in nonobese but insulin-resistant first-degree relatives of type 2 diabetic patients. Diabetes 2003; 52: 1182–1186
   PubMed Web of Science ®Google Scholar
• Tschritter O, Fritsche A, Thamer C, Haap M, Shirkavand F, Rahe S, Staiger H, Maerker E, Haring H, Stumvoll M. Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes 2003; 52: 239–243
   PubMed Web of Science ®Google Scholar
• Sieminska L, Marek B, Kos-Kudla B, Niedziolka D, Kajdaniuk D, Nowak W, Glogowska-Szelag J. Serum adiponectin in women with polycystic ovary syndrome. J Endocrinol Invest 2004; 27: 528–534
   PubMed Web of Science ®Google Scholar
• Gulcelik N, Aral Y, Serter R, Demir Y, Culha C. Adiponectin is an independent determinant of insulin resistance in women with polycystic ovary syndrome. Gynecol Endocrinol 2006; 22: 511–515
   PubMed Web of Science ®Google Scholar
• Marzullo P, Verti B, Savia G, Walker G E, Guzzaloni G, Tagliaferri M, Di Blasio A, Liuzzi A. The relationship between active ghrelin levels and human obesity involves alterations in resting energy expenditure. J Clin Endocrinol Metab 2004; 89: 936–939
   PubMed Web of Science ®Google Scholar
• McLaughlin T, Abbasi F, Lamendola C, Frayo R S, Cummings D. Plasma ghrelin concentrations are decreased in insulin-resistant obese adults relative to equally obese insulin-sensitive controls. J Clin Endocrinol Metab 2004; 89: 1630–1635
   PubMed Web of Science ®Google Scholar
• English P J, Ghatei M A, Malik I A, Bloom S R, Wilding J P. Food fails to suppress ghrelin in obese humans. J Clin Endocrinol Metab 2002; 87: 2984
   PubMed Web of Science ®Google Scholar
• Steinle N I, Pollin T I, O'Connell J R, Mitchell B D, Shuldiner A R. Variants in the ghrelin gene are associated with metabolic syndrome in the Old Order Amish. J Clin Endocrinol Metab 2005; 90: 6672–6677
   PubMed Web of Science ®Google Scholar
• Suematsu M, Katsuki A, Sumida Y, Gabazza E C, Murashima S, Matsumoto K, Kitagawa N, Akatsuka H, Hori Y, Nakatani K, et al. Decreased circulating levels of active ghrelin are associated with increased oxidative stress in obese subjects. Eur J Endocrinol 2005; 153: 403–407
   PubMed Web of Science ®Google Scholar
• Moran L J, Noakes M, Clifton P M, Wittert G A, Tomlinson L, Galletly C, Luscombe N D, Norman R J. Ghrelin and measures of satiety are altered in polycystic ovary syndrome but not differentially affected by diet composition. J Clin Endocrinol Metab 2004; 89: 3337–3344
   PubMed Web of Science ®Google Scholar
• Pagotto U, Gambineri A, Vincennati V, Heiman M L, Tschop M, Pasquali R. Plasma ghrelin, obesity, and polycystic ovary syndrome: correlation with insulin resistance and androgen levels. J Clin Endocrinol Metab 2002; 87: 5625–5629
   PubMed Web of Science ®Google Scholar